134,207 Shares in AtriCure, Inc. $ATRC Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 134,207 shares of the medical device company’s stock, valued at approximately $3,755,000.

A number of other hedge funds have also made changes to their positions in ATRC. Assenagon Asset Management S.A. purchased a new position in shares of AtriCure in the second quarter valued at approximately $1,744,000. F m Investments LLC purchased a new stake in shares of AtriCure during the fourth quarter worth approximately $2,872,000. Vanguard Group Inc. increased its position in shares of AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after purchasing an additional 62,861 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in AtriCure in the 1st quarter valued at $7,922,000. Finally, California State Teachers Retirement System raised its stake in AtriCure by 33.3% in the 1st quarter. California State Teachers Retirement System now owns 59,947 shares of the medical device company’s stock valued at $1,710,000 after purchasing an additional 14,987 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Price Performance

NASDAQ:ATRC opened at $44.77 on Tuesday. AtriCure, Inc. has a one year low of $25.36 and a one year high of $45.86. The stock has a market cap of $2.28 billion, a PE ratio of 213.20 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The stock has a 50 day moving average price of $34.27 and a 200 day moving average price of $31.52.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts expect that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Finally, Canaccord Genuity Group boosted their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and an average target price of $48.50.

Insider Buying and Selling at AtriCure

In other news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director owned 14,015 shares in the company, valued at $538,456.30. The trade was a 19.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at approximately $884,989.20. The trade was a 13.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 47,246 shares of company stock worth $1,777,845. Corporate insiders own 4.00% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.